Geodon Labeling Changes Still Under Discussion, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer is continuing to discuss new safety labeling for the antipsychotic Geodon (ziprasidone) with FDA, the company said in its April 20 earnings report
You may also be interested in...
Zyprexa Ekes Out Narrow Lead In Schizophrenia Study, But Efficacy Is Offset By Side Effects
CATIE study finds no significant difference in effectiveness between conventional antipsychotic perphenazine and three atypicals: AstraZeneca’s Seroquel, J&J’s Risperdal and Pfizer’s Geodon.
Zyprexa Ekes Out Narrow Lead In Schizophrenia Study, But Efficacy Is Offset By Side Effects
CATIE study finds no significant difference in effectiveness between conventional antipsychotic perphenazine and three atypicals: AstraZeneca’s Seroquel, J&J’s Risperdal and Pfizer’s Geodon.
J&J Risperdal "Dear Doctor" Letter Minimizes Diabetes Risk, FDA Ad Division Says
The agency warning letter says J&J inappropriately claimed that Risperdal is safer than other atypical antipsychotics. The company is working with FDA to address the agency's concerns as quickly as possible.